Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease

Blood (2024) 144 (Supplement 1): 4954.

https://doi.org/10.1182/blood-2024-204001

Published: 2024

Journal Articles

Exagamglogene Autotemcel for Severe Sickle Cell Disease

Blood (2023) 142 (Supplement 1): 1052.

https://doi.org/10.1182/blood-2023-190139

Published: 2023

Journal Articles

Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease

Haydar Frangoul, Franco Locatelli, Monica Bhatia, Markus Y. Mapara, Lyndsay Molinari, Akshay Sharma, Stephan Lobitz, Mariane de Montalembert, Damiano Rondelli, Martin Steinberg, Mark C. Walters, Suzan Imren, Lanju Zhang, Anjali Sharma, Yang Song, Christopher Simard, William Hobbs, Stephen Grupp

Blood (2022) 140 (Supplement 1): 29–31.

https://doi.org/10.1182/blood-2022-162353

Published: 2022

Journal Articles

Benefits of a Disease Management Program for SCD in Germany 2011 - 2019: The Increased Use of Hydroxyurea Correlates with a Reduced Frequency of Acute Chest Syndrome

Joachim B. Kunz, Andreas Schlotmann, Andrea Daubenbüchel, Stephan Lobitz, Andrea Jarisch, Regine Grosse, Holger Cario, Lena Oevermann, Dani Hakimeh, Laura Tagliaferri, Andreas E. Kulozik

Blood (2021) 138 (Supplement 1): 973.

https://doi.org/10.1182/blood-2021-148550

Published: 2021

Journal Articles

Hematological Presentation and Change in Clinical Phenotype during Follow-up in Pearson Syndrome

Ayami Yoshimi, MD PhD, Sarah C Grünert, MD, Holger Cario, MD PhD, Ute Gross-Wieltsch, MD, Udo Kontny, MD, Kyogo Suzuki, MD PhD, Stephan Lobitz, MD, Helen Wagner, MD, Irene Schmid, MD, Daniela Karall, MD, Arndt Borkhardt, MD, Miriam Erlacher, Peter Noellke, MPH, Charlotte M. Niemeyer, MD

Blood (2019) 134 (Supplement_1): 3746.

https://doi.org/10.1182/blood-2019-125199

Published: 2019

Journal Articles

Management of Infections in SCD Patients Treated with HU in the Framework of Escort HU

Frédéric Galactéros, MDPhD, Malika Benkerrou, MD, Mariane De Montalembert, MD PhD, Jean-Antoine Ribeil, MD, Corinne Pondarré, MD PhD, Jean Benoît Arlet, MD, Uwe Kordes, MD MRCP, Regine Grosse, MD, Valentine Brousse, MD, Lena Oevermann, MD, Stephan Lobitz, MD

Blood (2017) 130 (Supplement 1): 3543.

https://doi.org/10.1182/blood.V130.Suppl_1.3543.3543

Published: 2017

Journal Articles

Management of Renal Dysfunctions in Escort-HU Study

Pablo Bartolucci, MD PhD, Gylna Loko, MD, Corinne Charneau, MD, Jean-Antoine Ribeil, MD, Nathalie Lemonne, MD, Stephan Lobitz, MD, Malika Benkerrou, MD, Frederic Galacteros, MDPhD

Blood (2017) 130 (Supplement 1): 3528.

https://doi.org/10.1182/blood.V130.Suppl_1.3528.3528

Published: 2017

Journal Articles

Assessment of Hematological Data in a Cohort of European Children with Sickle Cell Anemia Treated with Hydroxyurea: Can European Centers Apply Today the Lessons from the Twitch Study?

Mariane De Montalembert, MD PhD, Malika Benkerrou, MD, Regine Grosse, MD, Uwe Kordes, MD MRCP, Valentine Brousse, MD, Corinne Pondarré, MD PhD, Corinne Armari-alla, MD, Narcisse Elenga, MD, Marcin Wlodarski, MD, Stephan Lobitz, MD

Blood (2016) 128 (22): 2494.

https://doi.org/10.1182/blood.V128.22.2494.2494

Published: 2016

Journal Articles

Comparison of the Safety Profile of Sickle Cell Disease Patients Treated with Hydroxycarbamide in Off-Label Versus in-Label Prescriptions in the Escort-HU Non Interventional, Prospective, Observational Open-Label Cohort Study

Ersi Voskaridou, MD, Stephan Lobitz, MD, Uwe Kordes, MD MRCP, Regine Grosse, MD, Valentine Brousse, MD, Malika Benkerrou, MD, Mariane De Montalembert, MD PhD, Jean-Antoine Ribeil, MD PhD, Frederic Galacteros, MD PhD

Blood (2016) 128 (22): 2497.

https://doi.org/10.1182/blood.V128.22.2497.2497

Published: 2016

Journal Articles

Effective Induction of Apoptosis by Mistletoe Plant Extracts in an Acute Lymphoblastic Leukemia Model.

Georg Seifert, MD, Patrick Jesse, MD, Aram Prokop, PhD, Tobias Reindl, MD, Stephan Lobitz, MD, Alfred Laengler, MD, Holger N. Lode, PhD, Guenter Henze, PhD

Blood (2006) 108 (11): 1880.

https://doi.org/10.1182/blood.V108.11.1880.1880

Published: 2006

Journal Articles

Enhancement of Lymphokine-Activated Killer Cell Cytotoxicity by Mistletoe Plant Extracts.

Georg Seifert, Holger N. Lode, MD, Stephan Lobitz, MD, Karl Seeger, MD, PhD, Alfred Laengler, MD, Guenter Henze, MD

Blood (2005) 106 (11): 3919.

https://doi.org/10.1182/blood.V106.11.3919.3919

Published: 2005

Journal Articles

High Sensitivity and Specificity of Retroviral Complementation Group Assignment in Primary T Cells of Fanconi Anemia (FA) Patients.

Helmut Hanenberg, MD, Stephan Lobitz, MD, Indira Kokemohr, MD, Silke Furlan, BS, Orna Levran, PhD, Arleen D. Auerbach, PhD, Reinhard Kalb, PhD, Michaela Gross, PhD, Richard Friedl, BS, B. Gottwald, BS, Detlev Schindler, MD

Blood (2004) 104 (11): 3249.

https://doi.org/10.1182/blood.V104.11.3249.3249

Published: 2004

NARROW

Durable Clinical Benefits with Exagamglogene Autotemcel for Severe Sickle Cell Disease

Exagamglogene Autotemcel for Severe Sickle Cell Disease

Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease

Benefits of a Disease Management Program for SCD in Germany 2011 - 2019: The Increased Use of Hydroxyurea Correlates with a Reduced Frequency of Acute Chest Syndrome

Hematological Presentation and Change in Clinical Phenotype during Follow-up in Pearson Syndrome

Management of Infections in SCD Patients Treated with HU in the Framework of Escort HU

Management of Renal Dysfunctions in Escort-HU Study

Assessment of Hematological Data in a Cohort of European Children with Sickle Cell Anemia Treated with Hydroxyurea: Can European Centers Apply Today the Lessons from the Twitch Study?

Comparison of the Safety Profile of Sickle Cell Disease Patients Treated with Hydroxycarbamide in Off-Label Versus in-Label Prescriptions in the Escort-HU Non Interventional, Prospective, Observational Open-Label Cohort Study

Effective Induction of Apoptosis by Mistletoe Plant Extracts in an Acute Lymphoblastic Leukemia Model.

Enhancement of Lymphokine-Activated Killer Cell Cytotoxicity by Mistletoe Plant Extracts.

High Sensitivity and Specificity of Retroviral Complementation Group Assignment in Primary T Cells of Fanconi Anemia (FA) Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only